P016 The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib G. Chen,Y. Zhang,H. Zhou,S. Zhao,J. Liu,S. Hong,L. ZhangJournal of Thoracic Oncology(2018)引用 0|浏览8暂无评分关键词nsclc,ALK,Brigatinib,AlectinibAI 理解论文溯源树样例生成溯源树,研究论文发展脉络